Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients

Abstract The influences of glutathione s-transferase P1, M1, and T1 variants on the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients were inconsistent in previous studies. Our meta-analysis enrolled 31 publications including 5712 patients and provided more convi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huan Ye, Meiqin Shao, Xiaohong Shi, Lifeng Wu, Bing Xu, Qiang Qu, Jian Qu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a184d10827824929a006d372aa2aa90f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a184d10827824929a006d372aa2aa90f
record_format	dspace
spelling	oai:doaj.org-article:a184d10827824929a006d372aa2aa90f2021-12-02T12:31:49ZPredictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients10.1038/s41598-017-02833-72045-2322https://doaj.org/article/a184d10827824929a006d372aa2aa90f2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02833-7https://doaj.org/toc/2045-2322Abstract The influences of glutathione s-transferase P1, M1, and T1 variants on the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients were inconsistent in previous studies. Our meta-analysis enrolled 31 publications including 5712 patients and provided more convincing and reliable conclusions. Results showed that GSTP1 IIe105Val IIe/Val and Val/Val Asian patients were more likely to have better response rates compared to IIe/IIe patients (odds ratio (OR) = 1.592, 95% confidence intervals (CIs), 1.087–2.332, P = 0.017). The Asian patients bearing the favorable GSTM1 null genotype were more likely to have better response rates to platinum-based chemotherapy compared to those patients with the unfavorable GSTM1 present genotype (OR = 1.493 (1.192–1.870), P < 0.001). Caucasian lung cancer patients bearing GSTT1 null genotype might be more closely associated with shorter survival time and higher risks of death than the GSTT1 present patients (hazard ratio (HR) = 1.423, CI = 1.084–1.869, P = 0.011). Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients. The use of GSTP1 IIe105Val, GSTM1 and GSTT1 null polymorphisms as predictive factors of efficacy of personalized platinum-based chemotherapy to NSCLC patients requires further verification with multi-center, multi-ethnic and large-sample-size pharmacogenetic studies.Huan YeMeiqin ShaoXiaohong ShiLifeng WuBing XuQiang QuJian QuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Huan Ye Meiqin Shao Xiaohong Shi Lifeng Wu Bing Xu Qiang Qu Jian Qu Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
description	Abstract The influences of glutathione s-transferase P1, M1, and T1 variants on the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients were inconsistent in previous studies. Our meta-analysis enrolled 31 publications including 5712 patients and provided more convincing and reliable conclusions. Results showed that GSTP1 IIe105Val IIe/Val and Val/Val Asian patients were more likely to have better response rates compared to IIe/IIe patients (odds ratio (OR) = 1.592, 95% confidence intervals (CIs), 1.087–2.332, P = 0.017). The Asian patients bearing the favorable GSTM1 null genotype were more likely to have better response rates to platinum-based chemotherapy compared to those patients with the unfavorable GSTM1 present genotype (OR = 1.493 (1.192–1.870), P < 0.001). Caucasian lung cancer patients bearing GSTT1 null genotype might be more closely associated with shorter survival time and higher risks of death than the GSTT1 present patients (hazard ratio (HR) = 1.423, CI = 1.084–1.869, P = 0.011). Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients. The use of GSTP1 IIe105Val, GSTM1 and GSTT1 null polymorphisms as predictive factors of efficacy of personalized platinum-based chemotherapy to NSCLC patients requires further verification with multi-center, multi-ethnic and large-sample-size pharmacogenetic studies.
format	article
author	Huan Ye Meiqin Shao Xiaohong Shi Lifeng Wu Bing Xu Qiang Qu Jian Qu
author_facet	Huan Ye Meiqin Shao Xiaohong Shi Lifeng Wu Bing Xu Qiang Qu Jian Qu
author_sort	Huan Ye
title	Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
title_short	Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
title_full	Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
title_fullStr	Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
title_full_unstemmed	Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
title_sort	predictive assessment in pharmacogenetics of glutathione s-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a184d10827824929a006d372aa2aa90f
work_keys_str_mv	AT huanye predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT meiqinshao predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT xiaohongshi predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT lifengwu predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT bingxu predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT qiangqu predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients AT jianqu predictiveassessmentinpharmacogeneticsofglutathionestransferasesgenesonefficacyofplatinumbasedchemotherapyinnonsmallcelllungcancerpatients
_version_	1718394296549244928

Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients

Ejemplares similares